4 Healthcare Stock Stories Ready for an Investment Checkup

Gentium S.p.A. (NASDAQ:GENT): Closing price $31.81

On Tuesday, Gentium reported┬áthat the European Commission has granted a Marketing Authorization for Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation therapy. Defitelio is the first okayed treatment in the European Union for this life-threatening condition. The authorization represents the formal endorsement of the positive opinion received from the European Medicine Agency’s Committee for Human Medicinal Product on July 26, 2013. Gentium intends to┬ácommence commercialization of Defitelio in the European Union in December.

GENT 20131022